Zacks Small Cap Analysis – RANI: GLP-2 Deal Introduced – Cyber Information
By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) introduced a collaboration with ProGen Co., Ltd. to develop an oral weight problems therapy combining ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 twin agonist PG-102. The press launch describing the deal was adopted by a convention name held the morning … Read more
